Franklin Biolabs provides objective, quantifiable data on immune cell infiltration within the tumor microenvironment (TME) using advanced IHC and digital image analysis. For immuno-oncology programs, this service delivers the robust, reproducible readouts necessary to de-risk candidate selection, demonstrate mechanism of action, and strengthen regulatory submissions for novel therapeutics.

The Challenge of Subjectivity in TME Assessment

Evaluating the TME is fundamental to immuno-oncology research. However, traditional manual pathology scoring of immune cell infiltration is semi-quantitative by nature and subject to inter-observer variability. This can introduce ambiguity into go/no-go decisions and complicate the interpretation of preclinical efficacy studies.

For therapeutic modalities designed to modulate the host immune response, precise and objective measurement is a core requirement. Regulatory bodies require reproducible data that clearly defines a drug candidate’s biological activity. Relying on subjective scoring methods can weaken a data package and delay program timelines.

A Quantitative Approach to Immune Infiltration

Digital pathology combined with automated image analysis removes the limitations of manual assessment. By converting stained tissue slides into high-resolution digital images, we can apply validated algorithms to generate objective data.

This methodology enables:

• Accurate Cell Counting: Precise enumeration of specific immune cell phenotypes (e.g., CD8+ cytotoxic T lymphocytes) within the tumor, stroma, or invasive margin.

• Spatial Characterization: Analysis of the proximity between different cell types, such as the distance of T-cells to tumor cells, providing mechanistic insights.

• High-Throughput Analysis: Consistent evaluation of large sample cohorts, ensuring statistical power and reliability across studies.

• Reproducible Scoring: Standardized quantification of protein expression (e.g., PD-L1) using metrics like H-score or percentage of positive cells.

.

Translating Preclinical Insights into Clinical Strategy

The principle of quantifying an immune response is a key translational bridge. For instance, research into vector-based therapeutics emphasizes the necessity of rigorously assessing host T-cell responses to understand potential immunogenicity (PMID: 29668327). This same scientific discipline is directly applicable to immuno-oncology, where the goal is to measure a desired therapeutic T-cell response against a tumor. A robust, quantitative assessment of immune cell activity is a foundational component of a successful development program.

At our >100,000 sq ft facility, we generate the high-integrity histology data that supports an accelerated 18-24 month IND timeline. This focus on quality underpins the legacy of the teams that now form Franklin Biolabs, which have maintained a 100% IND success rate since 2019. The Franklin Biolabs brand, launched in 2024, continues this commitment to scientific excellence.

“We greatly appreciate Franklin Bio Research Vector Team’s professionalism, responsiveness, and high-quality deliverables, which significantly contributed to the smooth execution. Highly recommended!”
— Franklin Biolabs Client